Cover Image
Market Research Report

Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2019

Published by GlobalData Product code 408771
Published Content info 309 Pages
Delivery time: 1-2 business days
Price
Back to Top
Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2019
Published: August 12, 2019 Content info: 309 Pages
Description

GlobalData's Medical Devices sector report, "Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2019", provides an overview of Continuous Glucose Monitoring Systems currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Continuous Glucose Monitoring Systems pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Continuous Glucose Monitoring Systems under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Continuous Glucose Monitoring Systems and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Continuous Glucose Monitoring Systems under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date.
Table of Contents
Product Code: GDME0788EPD

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Continuous Glucose Monitoring Systems Overview

3 Products under Development

  • 3.1 Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development
  • 3.2 Continuous Glucose Monitoring Systems - Pipeline Products by Territory
  • 3.3 Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path
  • 3.4 Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date
  • 3.5 Continuous Glucose Monitoring Systems - Ongoing Clinical Trials

4 Continuous Glucose Monitoring Systems - Pipeline Products under Development by Companies

  • 4.1 Continuous Glucose Monitoring Systems Companies - Pipeline Products by Stage of Development
  • 4.2 Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development

5 Continuous Glucose Monitoring Systems Companies and Product Overview

  • 5.1 A. Menarini Diagnostics Srl Company Overview
  • 5.2 Abbott Diabetes Care Inc Company Overview
  • 5.3 Advanced Biosensors-Ohio LLC (Inactive) Company Overview
  • 5.4 Advanced Medical Electronics Corp Company Overview
  • 5.5 Arkal Medical, Inc. (Inactive) Company Overview
  • 5.6 Ascensia Diabetes Care Holdings AG Company Overview
  • 5.7 Azurite Technologies, Inc. (Inactive) Company Overview
  • 5.8 Biorasis Inc Company Overview
  • 5.9 Biovotion AG Company Overview
  • 5.10 Brigham and Women's Hospital Company Overview
  • 5.11 CALISTO MEDICAL, INC. (Inactive) Company Overview
  • 5.12 CGM3 Ltd Company Overview
  • 5.13 City, University of London Company Overview
  • 5.14 Columbia University Company Overview
  • 5.15 ConvaTec Group Plc Company Overview
  • 5.16 Cyber Medical Ltd Company Overview
  • 5.17 Debiotech SA Company Overview
  • 5.18 DexCom Inc Company Overview
  • 5.19 DirectSens GmbH Company Overview
  • 5.20 Echo Therapeutics Inc Company Overview
  • 5.21 Ecole Polytechnique Federale de Lausanne Company Overview
  • 5.22 eLutions Integrated Systems, Inc. Company Overview
  • 5.23 EyeSense GmbH Company Overview
  • 5.24 Flowsion A/S Company Overview
  • 5.25 Gili Medical Ltd Company Overview
  • 5.26 Globe Medical Tech Inc (Inactive) Company Overview
  • 5.27 GlucoLight Corporation (Inactive) Company Overview
  • 5.28 Glucometrix AG Company Overview
  • 5.29 Glucosense Diagnostics Ltd (Inactive) Company Overview
  • 5.30 GlucoSet AS Company Overview
  • 5.31 Glucovation Inc Company Overview
  • 5.32 GluMetrics Inc Company Overview
  • 5.33 Glusense Ltd Company Overview
  • 5.34 GlySens Inc Company Overview
  • 5.35 G-Sense Ltd. Company Overview
  • 5.36 iGlyko, Inc. (Inactive) Company Overview
  • 5.37 Indigo Diabetes NV Company Overview
  • 5.38 Innovosens AB Company Overview
  • 5.39 Insulet Corp Company Overview
  • 5.40 Integrated Medical Sensors Company Overview
  • 5.41 Integrity Applications Ltd Company Overview
  • 5.42 Invivosense ASA (Inactive) Company Overview
  • 5.43 I-Sens Inc Company Overview
  • 5.44 iSense Corporation (Inactive) Company Overview
  • 5.45 Keratin Biosciences Inc Company Overview
  • 5.46 Know Labs Inc Company Overview
  • 5.47 KTH Royal Institute of Technology Company Overview
  • 5.48 LEMM Technologies, LLC Company Overview
  • 5.49 Massachusetts Institute of Technology Company Overview
  • 5.50 Medical Wireless Sensing Ltd Company Overview
  • 5.51 Medtronic Diabetes Company Overview
  • 5.52 Medtronic plc Company Overview
  • 5.53 Mellitor Ltd Company Overview
  • 5.54 Metronom Health Inc Company Overview
  • 5.55 mobiLIFE Company Overview
  • 5.56 Nemaura Medical Inc Company Overview
  • 5.57 Newton Photonics Inc Company Overview
  • 5.58 Northwestern University Company Overview
  • 5.59 Orsus Medical Ltd Company Overview
  • 5.60 Pkvitality Company Overview
  • 5.61 PositiveID Corp Company Overview
  • 5.62 Prediktor Medical AS Company Overview
  • 5.63 Profusa Inc Company Overview
  • 5.64 Purdue University Company Overview
  • 5.65 San Meditech (Huzhou) Co., Ltd. Company Overview
  • 5.66 Senseonics Holdings Inc Company Overview
  • 5.67 SensiVida Medical Technologies, Inc. (Inactive) Company Overview
  • 5.68 Senzime AB Company Overview
  • 5.69 Singapore Biomicro Pte Ltd Company Overview
  • 5.70 Socrates Health Solutions, Inc. Company Overview
  • 5.71 Stony Brook University Company Overview
  • 5.72 Swansea University Company Overview
  • 5.73 Tenax Therapeutics Inc Company Overview
  • 5.74 Terumo Corp Company Overview
  • 5.75 Texas A&M University Company Overview
  • 5.76 Ultradian Diagnostics LLC Company Overview
  • 5.77 University of California Berkeley Company Overview
  • 5.78 University of California Irvine Company Overview
  • 5.79 University of California San Diego Company Overview
  • 5.80 University of South Carolina Company Overview
  • 5.81 University of South Florida Company Overview
  • 5.82 University of Technology Sydney Company Overview
  • 5.83 University of Texas at Arlington Company Overview
  • 5.84 VeriTeQ Corporation Company Overview
  • 5.85 Vytrace, Inc. Company Overview
  • 5.86 WaveForm Technologies Inc Company Overview
  • 5.87 Zyvex Corp Company Overview

6 Continuous Glucose Monitoring Systems- Recent Developments

  • 6.1 Jul 24, 2019: Former Medtronic Executive Sean Ginney named VP of Sales at Current Health
  • 6.2 Jul 23, 2019: Edwards Lifesciences reports second quarter results for the year 2019
  • 6.3 Jul 18, 2019: Nemaura Medical appoints Chris Avery as vice president of global business operations to support global commercial launch of SugarBEAT
  • 6.4 Jul 17, 2019: Know Labs announces significant pre-clinical progress of uband non-invasive continuous glucose monitor
  • 6.5 Jul 10, 2019: Nemaura Medical submits de novo 510(k) application for SugarBEAT to the U.S. Food and Drug Administration
  • 6.6 Jul 08, 2019: Terumo invests 26 Million Euro in new production lines for its Belgian Facility
  • 6.7 Jun 27, 2019: FDA warns patients and health care providers about potential cybersecurity concerns with certain Medtronic insulin pumps
  • 6.8 Jun 25, 2019: ConvaTec Group: Board Change
  • 6.9 Jun 18, 2019: Senzime contracts new CFO
  • 6.10 Jun 17, 2019: Nemaura provides fiscal 2019 year-end business update
  • 6.11 Jun 17, 2019: Abbott reports second-quarter 2019 results
  • 6.12 Jun 11, 2019: Abbott's FreeStyle device helps significantly reduce glucose levels
  • 6.13 Jun 10, 2019: Real-World data from Guardian Connect and Sugar.IQ reveal improved diabetes outcomes
  • 6.14 Jun 08, 2019: Pilot Study Shows That Investigational Interconnected Diabetes Management Solution From Ascensia Significantly Reduced HbA1c in People With Type 2 Diabetes
  • 6.15 Jun 08, 2019: Medtronic initiates pivotal trial for next-generation Guardian Continuous Glucose Monitoring Sensor
  • 6.16 Jun 07, 2019: Senzime's board member Ulf Lindskog has passed away
  • 6.17 Jun 06, 2019: Senseonics announces FDA approval for a non-adjunctive indication (Dosing Claim) for the Eversense 90-day CGM System
  • 6.18 Jun 05, 2019: Senseonics to present real-world, long-term safety data of the First Implantable CGM Sensor at the American Diabetes Association's 79th Scientific Sessions
  • 6.19 Jun 04, 2019: Medtronic awarded $150M contract from Defense Logistics Agency

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer

List of Tables

  • Table 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development
  • Table 2: Continuous Glucose Monitoring Systems - Pipeline Products by Territory
  • Table 3: Continuous Glucose Monitoring Systems - Pipeline Product

List of Figures

  • Figure 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development
  • Figure 2: Continuous Glucose Monitoring Systems - Pipeline Products by Territory
  • Figure 3: Continuous Glucose Monitoring Systems - Pipeline Pro
Back to Top